Active Ingredient History

  • Now
Seladelpar is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.   Wikipedia

  • SMILES: CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc2ccc(OCC(=O)O)c(C)c2
  • Mol. Mass: 444.47
  • ALogP: 5.05
  • ChEMBL Molecules:
More Chemistry
(2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2h-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid | mbx-8025 | rwj-800025 | seladelpar


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue